




Searching News Database: icosapent
HSMN NewsFeed - 13 Sep 2017
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
HSMN NewsFeed - 19 Jan 2016
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
HSMN NewsFeed - 4 Feb 2014
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
HSMN NewsFeed - 13 Dec 2011
Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing
Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing
HSMN NewsFeed - 2 Feb 2011
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
HSMN NewsFeed - 8 Dec 2010
Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing
Catabasis Pharmaceuticals Secures $14.5 Million Second Tranche in Series A Financing
HSMN NewsFeed - 17 Aug 2010
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
HSMN NewsFeed - 2 Dec 2009
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairman
HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Additional items found! 4

Members Archive contains
4 additional stories matching:
icosapent
(Password required)
icosapent
(Password required)